Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Search content at Johns Hopkins University
Home
Profiles
Research units
Research output
Adjuvant and neoadjuvant therapy for pancreatic cancer
Shimpei Maeda
, Michiaki Unno
, Jun Yu
School of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Adjuvant and neoadjuvant therapy for pancreatic cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adjuvant Therapy
100%
Pancreatic Cancer
100%
Neoadjuvant Therapy
100%
Borderline Resectable Pancreatic Cancer
66%
Cancer Patients
33%
Chemotherapy
33%
Randomized Controlled Trial
33%
Randomized Trial
33%
Cancer Mortality
33%
Median Overall Survival
33%
Neoadjuvant
33%
Cancer Causes
33%
Survival Improvement
33%
Resectability Status
33%
Continuous Improvement
33%
Status Data
33%
Medicine and Dentistry
Adjuvant Therapy
100%
Pancreas Cancer
100%
Neoadjuvant Therapy
100%
Randomized Controlled Trial
20%
Malignant Neoplasm
20%
Overall Survival
20%
Chemotherapy
20%